Oncology

Investigators found a statistically significant improvement in both overall survival and progression-free survival for patients who received pembrolizumab with chemotherapy.

Low doses of propylparaben–a chemical preservative found in food, drugs, and cosmetics–can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer normally conveyed by pregnancy hormones.

The IGCS Mentorship and Training Program seeks to provide training and education to regions without formal training programs in gynecologic oncology.

Clinicians have been searching for accurate, reliable, non-invasive diagnostic tools to differentiate early stage, less dangerous, and more treatable stages of the disease from the aggressive, high-grade and likely-to-spread forms.

According to study results presented at the SGO meeting, biopsies showed no signs of cancer or precancer in two-thirds of 165 women with stage I endometrial cancer or atypical endometrial hyperplasia, 6 months after insertion of the hormonal IUD.

Language barriers can present a major obstacle to patient involvement in cancer care, although clinicians recommended several potential strategies to help patients who speak different languages.

The approach inverts missing alleles into an immune cell activating signal, which engineered T cells can then attack and destroy.

The FDA has granted priority review for an NDA for the hypoxia-inducible factor-2 alpha inhibitor MK-6482 for the potential treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma that does not require immediate surgery.

A panel of experts in the management of NETs discuss the role of peptide receptor radionuclide therapy for NETs.

The FDA announced that it will hold a public meeting of the Oncologic Drugs Advisory Committee from April 27 to 29 to address the indications granted accelerated approval for 6 therapies.

Bristol Myers Squibb and bluebird bio are seeking FDA approval for ide-cel as a standard therapy for relapsed myeloma, with a decision expected by the end of March.

The FDA has granted a fast track designation to poziotinib for use in previously treated non-small cell lung cancer patients with HER2 exon 20 mutations.

Dwight Kloth, PharmD, FCCP, BCOP, director of pharmacy at Fox Chase Cancer Center, discusses the role of the oncology pharmacist in the cancer care continuum, and how this role has been impacted by the COVID-19 pandemic.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, discuss the management of stomatitis caused by everolimus when used for NETs.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss the availability of home-injection programs for patients with NETs, especially during the coronavirus pandemic.

Experts in the management of NETs review the various delivery systems and preparations available for short- and long-acting somatostatin analogues.

The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.

Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.

Experts in the management of NETs discuss how the treatment landscape has evolved.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss when patients with NETs should be considered for active surveillance vs treatment.

A panel of experts in neuroendocrine tumors provide a definition of the disease and the diagnosis methods.

Pipeline drugs, expanding pharmacist roles, and a focus on COVID-19 vaccination are trends to watch for in 2021.

This model focuses sharply on orphan diseases to better address the patient experience, outcomes, and requirements of each study.

The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.

Investigators are set to begin testing sulfasalazine and auronofin, which are FDA-approved to treat rheumatoid arthritis, in cancer cell models.

Research over the past decade has shown that PV can be associated with a reduction in survival compared with age- and gender-matched population controls.

The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.